Using the Central American Free Trade Agreement (CAFTA), this book questions whether the human rights approach used by transnational groups to limit the effects of intellectual property rights in pharmaceutical access is an appropriate tool to face the challenges posed by global capitalism. Rather than using a theoretical approach, Godoy grounds her inquiry on the interface between transnational human rights advocates and the socio-political context, the health system, and local activists. Over the course of four years, she conducted in-depth interviews with a diverse array of stakeholders (including representatives of government and industry, patients and patient groups, trade negotiators and human rights activists) residing in Costa Rica, El Salvador and Guatemala. She complements her analysis using her in-depth knowledge of the region and the literature on human rights, globalisation and intellectual property (IP).
In the first chapter, Godoy explains the origins, relevance and methodology of her project. Chapter 2 deals with the history, actors and values that inspired the creation of the World Trade Organization and the regulations for protecting IP rights. Godoy also examines the history of the human rights movement, its growing interest in moving past political and civil rights to include economic and social rights, and the importance of adjusting its tactics to confront the challenges posed by the new global order. While human rights activists used to focus on limiting government's grip on political and civil liberties, now they want to empower governments to resist global pressures to adopt policies that will be detrimental to their communities.
Engaging people around IP rights requires new tools and images portraying the dimensions and human cost of IP policies that can capture the hearts and minds of broad audiences. Unfortunately, human rights language can be used to sustain the arguments of those in favour of IP protection (‘the right of inventors to enjoy the fruit of their innovation’), as well as those who consider that health and justice trump economic profits. Similarly, in the case of pharmaceuticals, IP stalls competition in order to protect the interests of global corporations and activists use economic arguments (market competition) to defend a human right.
Chapters 3 and 4 analyse the role of transnational human rights groups and their interactions and alignment with local activists, and the socio-political and health context. The pharmaceutical markets of El Salvador and Guatemala were underdeveloped and fraught with problems of access, quality and appropriate use. IP was an ill-understood threat of little immediate relevance that did not rally the interest of human rights and public health advocates. Most local activists prioritised fighting for basic rights (access to primary health care, water and sanitation) that, except in Costa Rica, remained unavailable for a large proportion of the population. The relative success of transnational human rights activists in mobilising local support faded as they left the region, probably due to their weak alignment with the local context. Weak advocacy and a socio-political context marred by loyalty conflicts (pressure from powerful governments, links with transnational corporations and the local pharmaceutical industry, and political rivalries), coupled with insufficient legal capacity to interpret the Agreement, resulted in significant regulatory differences among CAFTA's signatories. Surprisingly, the pharmaceutical products protected by IP rights differed in number and nature from country to country.
In Costa Rica, IP rights were broadly discussed and the Agreement was submitted to a referendum that divided the country. Costa Rican authorities, using a contested report, asserted that governments' pharmaceutical costs would not be affected and that maintaining good relations with the industry was of paramount importance for negotiating prices. Ultimately, the government signed and decided to concentrate on its regulations.
Chapter 5 describes how patients and patient groups used the courts and the right to health as a vehicle to gain access to expensive IP-protected medicines that they could not immediately access through the public health programmes. The courts tended to support the plaintiffs, bypassing the criteria of public health experts and prevailing IP regulations, which from the author's perspective exemplifies how the human-right-to-health approach can be used to reinforce the principles of capitalism.
The final chapter reconsiders Godoy's original question – are human rights ‘up to the challenge of confronting economic power’, or are they ‘little more than a fig leaf for economic exploitation’ (p. 129)? In contrast to those who believe that human rights can legitimise efforts to promote equity and justice, she concludes that today's formulation of human rights has strengthened the powerful. Godoy challenges human rights activists to discern when and how to use human rights approaches to foster social justice. She encourages activists not to lose sight of the root causes of the social struggle, warns against using market arguments to frame issues and advance human rights, and emphasises the importance of abandoning vertical approaches and instead connecting with local communities, responding to local contexts and using local discourses.
This book is a dense, provocative and detailed account of the failure of transnational human rights activists to persuade governments to rebuff the IP protections inserted in CAFTA. There are lessons to be learned, and I fully agree with the path proposed by Godoy; however, I also wonder if her expectations were too high. With the exception of Costa Rica, Central American countries are emerging from long and polarising civil wars, structural violence and corruption are pervasive, and the presence of narco-violence and gangs contributes to a climate of physical and socio-economic insecurity.
In addition, the negotiating power of these small countries is severely curtailed by the small size of their economies and their dependence on the United States. I would argue that the probability of success was low, and that this setback should not be interpreted as a failure of the human rights approach. We have just witnessed a case in Colombia, a country that has much in common with Central America, where the courts – using the constitutional human right to health – have forced the government and the manufacturer (Abbott) to set a lower price for Kaletra. It has been a long (five to six years) and difficult process, led by local activists connected to transnational groups. The slow and protracted nature of these procedures is one more reason to focus on listening to and empowering local actors. Granted, this victory will not radically change the global order in which we are immersed, but in the absence of a revolution, large policy changes are often reached through a series of incremental steps. We might yet see the emergence of Central American leaders who learned about the importance of IP and human rights during the CAFTA negotiations.
